Study S000027

A Multicenter, Randomized, Double-dummy, Placebo and Active-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Sitagliptin and Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin.

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00754988
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 666
Start: 2008-10
Primary completion: 2011-03
Lead sponsor: Hoffmann-La Roche
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG:Metformin; DRUG:Placebo (matching sitagliptin); DRUG:Placebo (matching taspoglutide); DRUG:Sitagliptin; DRUG:Taspoglutide
Results posted: FALSE
Secondary identifiers: OTHER:2008-001854-42; NIH:2008

Registered primary outcomes

Mean changes in HbA1c [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.